glp-1 agonists how do they work For Obesity In Non-Diabetic Patients: Game Changer Or Overhyped? A Critical Analysis GlobalRPH Mechanisms of action and therapeutic

Little is known about the association of discontinuation of sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RA) with outcomes in patients with CKD

Importantly, large-scale randomized trials, meta-analyses, and observational studies suggest that GLP-1RAs do not significantly increase AKI risk and may even confer renal benefits in high-risk populations

In this randomized clinical trial ...

Preclinical studies suggest that GIPR antagonism helps with weight loss and metabolic improvements

Glucagon-like peptide-1 (GLP-1) is one of the incretins that regulate glucose metabolism

As 2025 gets underway, we take a look at what lies ahead for the highly dynamic market for effective anti-obesity medications (AOMs)